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Abstract Glucose-stimulated expression of the insulin gene in L
cells is mediated by the PDX-1 transcription factor. In this
report, we show that stimulation results from effects on
activation and DNA-binding potential. Thus, glucose specifically
stimulated expression in MIN6 L cells from chimeras of PDX-1
and the GAL4 DNA-binding domain which spanned the N-
terminal PDX-1 activation domain located between amino acids
1 to 79. GAL4:PDX activity was induced over physiological
glucose concentrations and was also regulated by effectors of this
response. The level of endogenous PDX-1 binding and phospho-
rylation were also induced under these conditions. We discuss
how changes in PDX-1 phosphorylation may influence activity in
glucose-treated L cells.
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1. Introduction
In higher eukaryotes, glucose homeostasis is primarily con-
trolled through the concerted actions of glucagon and insulin
released from pancreatic islet K and L cells, respectively. These
hormones in£uence circulating blood glucose levels by e¡ect-
ing uptake and metabolism of this sugar in peripheral tissues
[1]. Insulin acts by reducing glucose levels, whereas glucagon
increases them. The primary physiological stimulus of insulin
transcription, synthesis, and release in the L cells is glucose
[2,3]. Metabolism of glucose in L cells is a requirement for
these events [4]. The identi¢cation and characterization of the
factors important in these processes provides insight into the
control mechanisms important in glucose sensing, and per-
haps, also, in the pathogenesis of islet dysfunction in non-
insulin-dependent diabetes mellitus.
Glucose-responsive and pancreatic L cell-speci¢c transcrip-
tion of the insulin gene is mediated by cis-acting elements
contained within the insulin enhancer region, which is located
between nucleotides 3340 to 391 relative to the transcription
start site [3,5]. The trans-acting factors that bind to and acti-
vate A3- (3213 to 3209 bp) [6^8], C1- (3115 to 3107 bp)
[9,10], and E1- (3100 to 391 bp) [9,11] driven expression
appear to be important in regulating both of these responses.
(The insulin cis elements are labeled in accordance with the
nomenclature of German et al. [12].) Thus, mutations that
decrease the binding a⁄nity of the A3, C1, and E1 activators
reduce both glucose-regulated and L cell-type-speci¢c tran-
scription from insulin gene reporter constructs. The PDX-1
homeodomain protein (also known as IPF1, STF-1, and
IDX-1 [13^15]) appears to be the principal regulator of insulin
A3 element-stimulated transcription [6,7]. The activator of E1
element-directed expression is a heterodimer, composed of
proteins in the basic helix-loop-helix (bHLH) family that are
enriched in islets (INSAF [16] or BETA2 [17,18]) and gener-
ally distributed (HEB [19] and E2A [20]). The C1 activator
has not been isolated.
Little is known about how glucose regulates A3, C1, and E1
activator function in L cells. Previously, it had been shown
that both C1- [9] and PDX-1- [8] binding activity were poten-
tiated in glucose-stimulated cells. In contrast, there is little
[21], or no increase [9] in E1 activator binding under these
same conditions. The recent observation that the phosphoryl-
ation level of PDX-1 is induced in glucose-stimulated cells
[22] suggests that activation of insulin transcription factor
function may be mediated by posttranslational modi¢cation
mechanisms (for review, see [23]) that in£uence either the
binding and/or activation potential of the A3, C1, and E1
activators.
To begin to investigate this issue, we analyzed how PDX-1
activity was stimulated by glucose in MIN6 L cells and rat
islets. Recent studies have shown that the transactivation do-
main of PDX-1 was contained within the N-terminal region
sequences spanned by amino acids 1^79 [24]. Results obtained
with chimeras between PDX-1 and the DNA-binding domain
of the Saccharomyces cerevisiae transcription factor GAL4
revealed that PDX-1 transactivation domain activity was in-
duced in glucose-stimulated L cells. Under these conditions,
the level of phosphorylation and binding of PDX-1 were also
induced. These results suggest that glucose in£uences both the
binding and transactivation potential of PDX-1 in L cells. We
discuss the possible importance of phosphorylation mecha-
nisms in these activation processes.
2. Materials and methods
2.1. Cell lines and nuclear extract preparation
MIN6 L cells [25] were grown in DMEM containing 4.5 g glucose/l
(GIBCO), 15% fetal calf serum (Sera-lab, Crawley Down, Sussex,
UK), penicillin (100 U/ml), streptomycin (100 mg/ml) (GIBCO/
BRL), and 50 WM L-mercaptoethanol. Nuclear extracts were prepared
from 108 cells by modi¢cation of the procedure described in [26].
2.2. Transfections
A 60% con£uent 6 cm2 dish of MIN6 cells was transfected by the
calcium co-precipitation method [27]. The islets were isolated from
newborn rats [28] and left for 7 days in RPMI 1640 with 0.5% human
serum to remove ¢broblasts. The islets were then made into single
cells by trypsinization, and single cells from 500 islets were transfected
FEBS 20539 24-7-98
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 0 7 7 6 - 5
*Corresponding author. Fax: +45 (4443) 8000.
E-mail: pas@hagedorn.dk
FEBS 20539FEBS Letters 431 (1998) 362^366
by Lipofectamine (Promega) in OPTIMEM (GIBCO). The DNA
transfections contained a GAL4 expression construct,
(GAL4)5E1bCAT [29], and pGL2RSV luciferase (Promega). (The
construction of each of the GAL:PDX wild-type and mutant con-
structs [24] and GAL4:VP16 [30] has been described.) The luciferase
activity from pGL2RSV luciferase was used as a control. After trans-
fection, the cells were grown in RPMI 1640 (10% FCS) containing
either 3 or 20 mM glucose. The cells were harvested after 16 h, and
luciferase (Promega) and chloramphenicol acetyltransferase (CAT)
assays [27] performed. The CAT activity of each sample was normal-
ized to the protein content (Biorad) of the extract.
2.3. Electrophoretic mobility shift assay
The electrophoretic mobility shift assay (EMSA) was performed
using 5 Wg of MIN6 nuclear extract and the human A3 element probe
(5P CCCCTGGTTAAGACTCTAAGGACCCGCTGG 3P) as de-
scribed by Petersen et al. [6]. One Wl of the preimmune or 1858
KPDX-1 antiserum was added prior to the addition of oligonucleo-
tide. The 1858 KPDX-1 antiserum was raised against rat PDX-1 se-
quences spanning 221 to 284 [31].
2.4. Immunoblots
MIN6 and islet cells were incubated at 37‡C in DME (Gibco) with
3 mM glucose for 90 min. 32P-labeled inorganic phosphate (Amer-
sham, ¢nal concentration 0.3 mCi/ml media) was then added and
incubated at 37‡C for 2 h in either 3 or 20 mM glucose. Whole cell
extracts were prepared as described previously [32]. Two hundred Wl
of extract was incubated for 1 h with 2 Wl of either the preimmune or
1858 KPDX-1 antiserum in lysis bu¡er (20 mM Imidazole-HCl pH
6.8, 100 mM KCl, 1 mM MgCl2, 10 mM EGTA, 0.2% Triton X-100,
10 mM NaF, 1 mM sodium vanadate, 1 mM sodium molybdate,
1 mM AEBSF). The PDX-1:Protein A Sepharose precipitated com-
plexes were prepared as described previously [33] except that TBST
bu¡er was exchanged with lysis bu¡er and resolved on a 10% SDS-
polyacrylamide gel. The gel was dried and labeled protein bands
visualized by autoradiography.
Immunoblots were performed as described [34] using 15 Wg of nu-
clear extract that was resolved on a 10% SDS-polyacrylamide gel.
KPDX-1 antiserum [31] or preimmune serum was used as primary
antibody.
3. Results
3.1. Glucose stimulates the transactivation domain potential of
PDX-1
To determine whether the transactivation domain function
of PDX-1 was regulated by glucose, a series of PDX-1 mu-
tants spanning the N-terminal activation domain were ana-
lyzed as fusion proteins to the DNA-binding domain of the
Saccharomyces cerevisiae GAL4 transcription factor. The ef-
fect of glucose on herpes virus VP16 activation domain stimu-
lated GAL4 expression and insulin enhancer-mediated activity
was compared to the GAL4:PDX-1 response in these assays.
The GAL4 fusion protein expression plasmids were cotrans-
fected into MIN6 L cells and isolated rat islet cells along with
a CAT reporter plasmid containing ¢ve GAL4 DNA-binding
sites upstream of the E1b TATA. The transfected cells were
then incubated in either 3 or 20 mM glucose containing me-
dium for 16 h. Insulin secretion from MIN6 cells is stimulated
under these conditions [25].
Each of the GAL4:PDX-1 fusion constructs was glucose-
responsive (Fig. 1A and B). However, the GAL4:PDX-1 plas-
mids containing homeobox sequences (GAL4:PDX 1^284 and
GAL4:PDX 1^220) were stimulated less e¡ectively by glucose
than the N-terminal PDX-1 fusion construct, GAL4:PDX 1^
149 in MIN6 cells. Importantly, GAL4:PDX 1^149 was re-
sponsive within the same range of glucose concentrations as
the insulin enhancer construct, rINS:CAT, in both MIN6 and
islet cells (Fig. 1B and C). In contrast, GAL4:VP16 was only
slightly responsive to glucose while the GAL4 cloning vector
alone was unresponsive. These results suggested that glucose
potentiated the transactivation capabilities of PDX-1 by alter-
ing transactivation domain-mediated stimulation.
Previously it had been shown that glucose-treatment causes
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Fig. 1. Transactivation by PDX-1 is potentiated in glucose-stimu-
lated MIN6 cells. A: Diagrammatic representation of the
GAL4:PDX, GAL4:PDX 1^220, and GAL4:PDX 1^149 constructs.
The activation and homeodomain regions span amino acids 1^79
and 146^206, respectively [24,38,43]. B: MIN6 cells and C: isolated
rat islet cells were transfected with the GAL4 fusion vector,
GAL4:PDX or GAL4:VP16 (2.5 Wg) and (GAL4)5E1bCAT (5 Wg),
or rINS:CAT (7.5 Wg), along with pGL2 RSV luciferase (2.5 Wg)
(rINS:CAT contains 346 bp of the rat insulin I gene promoter fused
to CAT [44]). The results are calculated as the ratio of the normal-
ized CAT activity at 20 mM glucose divided by 3 mM þ S.E.M.
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an increase in both the PDX-1-binding activity [8,22] and
phosphorylation state [22] in islet L cells. We also found
that the level of PDX-1 binding (Fig. 2A), as well as its phos-
phorylation level (Fig. 2B), increased in MIN6 cells grown
under basal (3 mM) versus stimulating (20 mM) glucose con-
centrations. The state of phosphorylation also increased after
glucose-treatment of rat islets (Fig. 2C). In contrast, these
conditions did not in£uence the steady-state PDX-1 levels in
MIN6 cells (Fig. 2D). Together, these data indicate that PDX-
1 activation in glucose-stimulated L cells was meditated
through changes in both the transactivation and DNA-bind-
ing potential of the protein.
3.2. Metabolic regulation of GAL4:PDX 1^149 activity
Metabolism of glucose in pancreatic L cells generates an
intracellular signal(s) that results in increased insulin secre-
tion, insulin biosynthesis, and insulin transcription [2,3,35].
We next examined whether GAL4:PDX 1^149 activity in
MIN6 cells was regulated by physiological glucose concentra-
tions, and by factors that can either substitute (i.e. mannose)
or inhibit (i.e. 2-deoxy glucose) glucose metabolism. As a
positive control, insulin enhancer-mediated activity (i.e.
hINS:CAT) was analyzed in MIN6 cells transfected and
treated in parallel with the GAL4:PDX 1^149 experimental
samples.
Nearly superimposable glucose response curves were ob-
tained from GAL4:PDX 1^149 and hINS:CAT (Fig. 3).
The apparent half-maximal glucose concentration required
for transcriptional activation was also similar to that of in-
sulin secretion in islets (EC50S of 9 mM [36]), suggesting that
the inductive signal(s) for these distinct responses are gener-
ated under similar glucose concentrations. The results of our
e¡ector studies suggest that GAL4:PDX 1^149 activity is also
regulated by factors that in£uence insulin expression in islets.
Thus, the non-metabolizable glucose analog, 2-deoxy glucose,
inhibited both glucose-induced GAL4:PDX 1^149 and insulin
enhancer-mediated activation to the same degree (Fig. 4). In
addition, both of these glucose-sensitive activities were stimu-
lated to a comparable level when the metabolizable glycolytic
(i.e. mannose) cycle substrate was analyzed. These results pro-
vide additional evidence indicating that the activation poten-
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Fig. 2. PDX-1-binding and phosphorylation levels in glucose-stimulated MIN6 cells. A: PDX-1-binding activity in glucose-treated MIN6 cells.
The EMSA was performed with nuclear extracts prepared from 3 or 20 mM glucose-treated MIN6 cells. The extracts were preincubated in the
absence of serum (3serum), preimmune serum (PI), or KPDX-1 antiserum, and then binding activity determined using the human A3 element
probe. B: PDX-1 phosphorylation level in glucose-treated MIN6 cells. The cells were grown in either 3 or 20 mM glucose plus 32P-labeled inor-
ganic phosphate. PDX-1 levels were determined by immunoprecipitation with increasing amounts of KPDX-1 antiserum and preimmune (PI) se-
rum. The arrow denotes the position of PDX-1 in the blot. C: PDX-1 phosphorylation level in glucose-treated isolated islet cells. Same experi-
ment as in B except that immunoprecipitation was carried out using the same amount of KPDX-1 antiserum and preimmune (PI) serum. D:
The steady-state level of PDX-1 in glucose-treated MIN6 cells.
Fig. 3. GAL4:PDX 1^149 and hINS:CAT activity are co-regulated
in glucose-treated MIN6 cells. MIN6 cells were transfected with
hINS:CAT (7.5 Wg), a CAT construct driven by 337 bp of the hu-
man insulin 5P-enhancer:promoter region [6], or GAL4:PDX 1^149
(2.5 Wg) at the indicated glucose concentrations. The results shown
are the mean of at least two experiments performed in duplicate.
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tial of PDX-1 is an important functional determinant for glu-
cose-induced transcription.
4. Discussion
The principal physiological regulator of insulin transcrip-
tion in islet L cells is glucose. Previously it had been shown
that the A3 element, which resides within the insulin enhancer
region, mediates glucose-inducible transcription [6]. Further-
more, stimulation appeared to result from induced binding of
the A3 activator, PDX-1 [8,22,37]. In this study, the molecular
basis for activation was further de¢ned. We have shown that
glucose not only induces the transactivation potential of
PDX-1 by e¡ecting DNA binding, but also by stimulating
transactivation domain function. Importantly, transcriptional
activation by GAL:PDX responded to both physiological glu-
cose concentrations as well as normal L cell e¡ectors (i.e.
mannose and 2-deoxy glucose). We conclude that modi¢ca-
tions in both DNA-binding and transactivation capacity en-
able PDX-1 to mediate glucose-inducible insulin gene tran-
scription in islet L cells.
Studies conducted in a number of di¡erent laboratories
strongly indicate that PDX-1 is an important activator of
the insulin gene [6,7,13,31,38,39]. The observation that the
nuclei of essentially all insulin-producing islet L cells contain
PDX-1, yet it’s only present in a small subset of the other islet
hormone-producing cells, also supports this hypothesis
[31,38,40]. However, evidence showing that PDX-1 is not re-
quired for insulin gene transcription has come from the anal-
ysis of pdx-1 mutant mice. Thus, even though pancreas for-
mation is prevented in pdx-13=3 mice [41], insulin positive
cells were transiently detected during embryonic development
[42]. In addition, we recently found that insulin gene expres-
sion proceeded in the absence of PDX-1 in LTC-3 cells stably
transfected with the PDX-1 transactivation mutant,
vABC:PDX-1 [24] albeit with insulin gene transcription re-
duced by 75%. These results indicate that PDX-1 is not re-
quired for insulin gene transcription per se, but do contribute
to the high transcriptional activity of the insulin gene in L
cells. Since the function of PDX-1 in glucose-induced insulin
gene expression would not have been discerned in these ex-
perimental systems we still strongly believe that this factor
plays an essential regulatory role in this response.
In our analyses, the phosphorylation state of PDX-1 in-
creased in parallel with its binding and activation potential
in glucose-treated L cells. Unfortunately, the site(s) of modi-
¢cation within PDX-1 have not been identi¢ed.
It is our objective to understand the roles these factors play
in PDX-1 function by analyzing how their interplay deter-
mines developmental and inducible transcriptional activation.
Acknowledgements: This work was supported by the Danish National
Research Foundation (P.S. and O.D.M. [Center for Gene Regulation
and Plasticity in the Neuroendocrine Network]), the Juvenile Diabetes
Foundation International (#394131 to H.V.P., and #197122 to
O.D.M.), the Danish Research Councils (#12-2302-1 to H.V.P.) and
the National Institutes of Health grants (NIH RO1 DK50203 and DK
49852 to R.S.) and partial support was also derived from the Vander-
bilt University Diabetes Research and Training Center Molecular Bi-
ology Core Laboratory (Public Health Service grant P60 DK20593
from the National Institutes of Health). The Hagedorn Research In-
stitute is an independent basic research component of Novo Nordisk.
References
[1] Darnell, J., Lodish, H. and Baltimore, D. (1990) in: Molecular
Cell Biology, Scienti¢c american books, New York, pp. 613^616
and 743^745.
[2] Docherty, K. and Clark, A. (1994) FASEB J. 8, 21^27.
[3] Stein, R. (1993) Trends Endocrinol. Metab. 4, 96^101.
[4] German, M.S. (1993) Proc. Natl. Acad. Sci. USA 90, 1781^1785.
[5] Philippe, J. (1994) Endocrine Rev. 2, 21^27.
[6] Petersen, H.V., Serup, P., Leonard, J., Michelsen, B.K. and Mad-
sen, O.D. (1994) Proc. Natl. Acad. Sci. USA 91, 10465^10469.
[7] Serup, P., Petersen, H.V., Petersen, E.E., Edlund, H., Leonard,
J., Petersen, J.S., Larsson, L.-I. and Madsen, O.D. (1995) Bio-
chem. J. 310, 997^1003.
[8] Melloul, D., Ben-Neriah, Y. and Cerasi, E. (1993) Proc. Natl.
Acad. Sci. USA 90, 3865^3869.
[9] Sharma, A. and Stein, R. (1994) Mol. Cell. Biol. 14, 871^879.
[10] Sharma, A., Fusco-DeMane, D., Henderson, E., Efrat, S. and
Stein, R. (1995) Mol. Endocrinol. 9, 1468^1476.
[11] Odagiri, H., Wang, J. and German, M.S. (1996) J. Biol. Chem.
271, 1909^1915.
[12] German, M. et al. (1995) Diabetes 44, 1002^1004.
[13] Ohlsson, H., Karlsson, K. and Edlund, T. (1993) EMBO J. 12,
4251^4259.
[14] Leonard, J., Peers, B., Johnson, T., Ferreri, K., Lee, S. and
Montminy, M.R. (1993) Mol. Endocrinol. 7, 1275^1283.
[15] Miller, C.P., McGehee, R.E. and Habener, J.F. (1994) EMBO J.
13, 1145^1156.
[16] Robinson, G., Cordle, S., Henderson, E., Weil, P., Teitelman, G.
and Stein, R. (1994) Mol. Cell. Biol. 14, 6704^6714.
[17] Naya, F.J., Stellrecht, C.M. and Tsai, M.J. (1995) Genes Dev. 9,
1009^1019.
[18] Lee, J.E., Hollenberg, S.M., Snider, L., Turner, D.L., Lipnick, N.
and Weintraub, H. (1995) Science 268, 836^844.
[19] Peyton, M., Moss, L.G. and Tsai, M.-J. (1994) J. Biol. Chem.
269, 25936^25941.
[20] Nelson, C., Shen, L.-P., Meister, A., Fodor, E. and Rutter, W.J.
(1990) Genes Dev. 4, 1035^1043.
[21] German, M. and Wang, J. (1994) Mol. Cell. Biol. 14, 4067^4075.
[22] MacFarlane, W.M., Read, M.L., Gilligan, M., Bujalska, I. and
Docherty, K. (1994) Biochem. J. 303, 625^631.
[23] Karin, M. and Hunter, T. (1995) Curr. Biol. 5, 747^757.
[24] Peshavaria, M., Henderson, E., Sharma, A., Wright, C. and
Stein, R. (1997) Mol. Cell. Biol. 17, 3987^3996.
[25] Miazaki, J.-I., Araki, K., Yamato, E., Ikegami, H., Asano, T.,
Shibasaki, Y., Oka, Y. and Tamamura, K.-I. (1990) Endocrinol-
ogy 127, 126^132.
FEBS 20539 24-7-98
Fig. 4. Regulation of GAL4:PDX 1^149-mediated activation by ef-
fectors of glucose-stimulated expression. MIN6 cells and rat islets
were transfected with GAL4:PDX 1^149 or rINS:CAT as described
in Fig. 1B. The cells were grown in the presence of either 3 mM
glucose, 20 mM glucose, 20 mM mannose or 20 mM 2-deoxy glu-
cose. A representative experiment is shown. Results are given as the
percentage of the glucose-stimulated expression.
H.V. Petersen et al./FEBS Letters 431 (1998) 362^366 365
[26] Schreiber, E., Mathias, P., Muller, M. and Schafner, W. (1988)
EMBO J. 7, 4221^4229.
[27] Gorman, C. (1985) in: D. Glover (Ed.), DNA Cloning, A Prac-
tical Approach, Vol. II, IRL-Press, Oxford University, New
York, pp. 143^190.
[28] Brunstedt, J. (1980) Diabete Metab. 6, 87^89.
[29] Sadowski, I. and Ptashne, M. (1989) Nucleic Acids Res. 17, 7539.
[30] Sadowski, I., Ma, J., Triezenberg, S. and Ptashne, M. (1988)
Nature 335, 563^564.
[31] Serup, P., Jensen, J., Andersen, F., JÖrgensen, M., Blume, N.,
Holst, J. and Madsen, O. (1996) Proc. Natl. Acad. Sci. USA 93,
9015^9020.
[32] Hopkirk, T. and Denton, R. (1986) Biochim. Biophys. Acta 885,
195^205.
[33] Petersen, J. et al. (1994) Diabetes 43, 459^467.
[34] MÖller, C.J., Christgau, S., Williamson, M.R., Madsen, O.D.,
Zhan-Po, N., Bock, E. and B×kkeskov, S. (1992) Mol. Endocri-
nol. 6, 1332^1342.
[35] Efrat, S., Tal, M. and Lodish, H. (1994) TIBS 19, 535^538.
[36] Megallsson, M. and Matschinsky, F. (1986) Diabetes Metab.
Rev. 2, 163^214.
[37] Marshak, S., Totary, H., Cerasi, E. and Melloul, D. (1996) Proc.
Natl. Acad. Sci. USA 93, 15057^15062.
[38] Peers, B., Leonard, J., Sharma, S., Teitelman, G. and Montminy,
M.R. (1994) Mol. Endocrinol. 8, 1798^1806.
[39] Watada, H. et al. (1996) Diabetes 45, 1826^1831.
[40] Peshavaria, M., Gamer, L., Henderson, E., Teitelman, G.,
Wrigh, C. and Stein, R. (1994) Mol. Endocrinol. 8, 806^816.
[41] Jonsson, J., Carlsson, L., Edlund, T. and Edlund, H. (1994)
Nature 371, 606^609.
[42] Ahlgren, U., Jonsson, J. and Edlund, H. (1996) Development
122, 1409^1416.
[43] Lu, M., Miller, C. and Habener, J. (1996) Endocrinology 137,
2959^2967.
[44] Karlsson, O., Edlund, T., Moss, J.B., Rutter, W.J. and Walker,
M.D. (1987) Proc. Natl. Acad. Sci. USA 84, 8819^8823.
FEBS 20539 24-7-98
H.V. Petersen et al./FEBS Letters 431 (1998) 362^366366
